Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in ADPT — Adaptive Biotechnologies Corp

CIK 1423053 MIAMI, FL
Back to ADPT Full portfolio

Position in ADPT

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$5,043,061
+$4,118,161 QoQ
Shares Held
363,333
+538.0% QoQ
Ownership
0.227%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
24 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in ADPT Over Time

Shares Held

Position Value (USD)

Derivatives in ADPT

reported options exposure · as of Mar 31, 2026
CallValue
$202,648
CallShares
14,600
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Diagnostics & Research

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $1,657,068,556 across 34 Diagnostics & Research names. ADPT ranks #19 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 TMO
Thermo Fisher Scientific Inc.
 864,489 $424,922,277
2 CRL
Charles River Laboratories International, Inc.
 1,212,152 $209,096,220
3 A
Agilent Technologies, Inc.
 1,801,714 $205,359,361
4 DHR
Danaher Corp /De/
 1,026,347 $194,595,390
5 MTD
Mettler Toledo International Inc/
 58,054 $73,217,704
6 GH
Guardant Health, Inc.
 775,941 $71,673,669
7 DGX
Quest Diagnostics Inc
 347,218 $68,047,783
8 IQV
Iqvia Holdings Inc.
 390,042 $66,517,762

All Filings in ADPT

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $5,043,061 363,333
2026-03-31 $202,648 14,600
2025-12-31 $354,032 21,800
2025-12-31 $924,900 56,952
2025-09-30 $420,136 28,084
2025-09-30 $179,520 12,000
2025-06-30 $9,328,026 800,689
2025-06-30 $209,700 18,000
2025-03-31 $204,325 27,500
2025-03-31 $138,198 18,600
2025-03-31 $1,072,431 144,338
2024-12-31 $40,766 6,800
2024-12-31 $1,360,756 226,982
2024-12-31 $50,957 8,500
2024-09-30 $193,024 37,700
2024-09-30 $1,072,260 209,426
2024-09-30 $151,040 29,500
2024-06-30 $56,110 15,500
2024-06-30 $30,408 8,400
2024-06-30 $1,455,681 402,122
2024-03-31 $33,384 10,400
2024-03-31 $8,346 2,600
2024-03-31 $262,892 81,898
2023-12-31 $192,570 39,300
2023-12-31 $62,720 12,800
2023-12-31 $14,067 2,871
2023-09-30 $94,830 17,400
2023-09-30 $784,756 143,992
2023-09-30 $53,955 9,900
2023-06-30 $93,269 13,900
2023-06-30 $4,794,442 714,522
2023-06-30 $148,291 22,100
2023-03-31 $261,368 29,600
2023-03-31 $7,086,101 802,503
2023-03-31 $90,949 10,300
2022-12-31 $120,712 15,800
2022-12-31 $4,150,643 543,278
2022-12-31 $345,328 45,200
2022-09-30 $249,200 35,000
2022-09-30 $5,951,002 835,815
2022-09-30 $158,064 22,200
2022-06-30 $340,589 42,100
2022-06-30 $3,248,692 401,569
2022-06-30 $221,666 27,400
2022-03-31 $620,436 44,700
2022-03-31 $977,152 70,400
2022-03-31 $2,801,968 201,871
2021-12-31 $572,424 20,400
2021-12-31 $4,770,760 170,020
2021-12-31 $791,292 28,200

Report a Problem

Category
Description
Email (optional, for follow-up)